IMVT
Immunovant, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -15.4% ·
share flow -15.3% ·
net new positions -18.2%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | +8 | 58.13M | $2.24B | +14 | −5 |
| Q1 2026 | 86 | +8 | 53.00M | $1.32B | +12 | −4 |
| Q4 2025 | 78 | -2 | 55.44M | $1.41B | — | −2 |
| Q3 2025 | 16 | 0 | 40.91M | $659.48M | +1 | −2 |
| Q2 2025 | 14 | -2 | 41.55M | $664.87M | — | −2 |
| Q1 2025 | 13 | +2 | 9.17M | $156.74M | +2 | — |
| Q4 2024 | 11 | -2 | 8.24M | $204.11M | — | −2 |
| Q3 2024 | 12 | +1 | 7.03M | $200.30M | +1 | — |
| Q2 2024 | 11 | — | 7.29M | $192.47M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 2.70M | — | $66.82M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.52M | +0.3% | $37.54M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.52M | +0.3% | $37.54M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Viking Global Investors ✦ | 1.41M | -39.4% | $34.86M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 916.25K | -24.2% | $22.70M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 916.25K | -24.2% | $22.70M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 637.95K | +13.2% | $15.80M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 444.01K | +30.6% | $11.00M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 444.01K | +30.6% | $11.00M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 300.00K | 0.0% | $7.43M | 0.0% | Held | 3 | SEC ↗ |
| 11 | Millennium Management ✦ | 147.10K | -60.9% | $3.64M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 80.90K | -57.2% | $2.00M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 67.67K | +8.4% | $1.68M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 67.67K | +8.4% | $1.68M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | Wellington Management ✦ | 26.27K | -8.4% | $650,684 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Wellington Management ✦ | 26.27K | -8.4% | $650,684 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Wellington Management ✦ | 26.27K | -8.4% | $650,684 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Wellington Management ✦ | 26.27K | -8.4% | $650,684 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $3.25M | was 0.0% |
| AQR Capital Management | $287,438 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 215 holders, 110.50M shares, $2.64B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.06K sh · $134,953
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology